At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GERN Geron
Post-Mkt 12-19 16:01:51 EST
1.33
-0.01
-0.75%
盘后1.33
+0.000.00%
16:01 EST
High1.36Low1.31Vol10.91M
Open1.36D1 Closing1.34Amplitude3.73%
Mkt Cap849.01MTradable Cap710.33MTotal Shares638.36M
T/O14.50MT/O Rate2.04%Tradable Shares534.08M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  12-19 05:30
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks
Benzinga_recent_news  ·  12-19 02:05
Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks
Geron Corp - Begins Strategic Restructuring Plan - SEC Filing
THOMSON REUTERS  ·  12-17 05:02
Geron Corp - Begins Strategic Restructuring Plan - SEC Filing
Geron Corporation Announces Workforce Reduction and $18 Million Restructuring Charge
Reuters  ·  12-17 05:02
Geron Corporation Announces Workforce Reduction and $18 Million Restructuring Charge
Geron Shares up 2.3% Premarket; Co Announces Strategic Restructuring Plan to Reduce Workforce by One-Third
THOMSON REUTERS  ·  12-11
Geron Shares up 2.3% Premarket; Co Announces Strategic Restructuring Plan to Reduce Workforce by One-Third
BRIEF-Geron Corporation Announces Strategic Restructuring Plan To Position The Company For Long-Term Value Creation
Reuters  ·  12-11
BRIEF-Geron Corporation Announces Strategic Restructuring Plan To Position The Company For Long-Term Value Creation
Geron Corporation Cuts Workforce by One-Third in Strategic Restructuring
Reuters  ·  12-11
Geron Corporation Cuts Workforce by One-Third in Strategic Restructuring
Geron Corp - 2026 Operating Expenses Expected to Be Less Than 2025
THOMSON REUTERS  ·  12-11
Geron Corp - 2026 Operating Expenses Expected to Be Less Than 2025
Geron Corp - Restructuring Plan to Reduce Workforce by One-Third
THOMSON REUTERS  ·  12-11
Geron Corp - Restructuring Plan to Reduce Workforce by One-Third
Geron Corp - to Incur Cash-Based Restructuring Charges
THOMSON REUTERS  ·  12-11
Geron Corp - to Incur Cash-Based Restructuring Charges
Geron Corp: Reduction in Geron's Current Workforce of About 260 Employees
THOMSON REUTERS  ·  12-11
Geron Corp: Reduction in Geron's Current Workforce of About 260 Employees
Geron Corp: Restructuring Plan Is Expected to Be Substantially Complete in Q1 of 2026
THOMSON REUTERS  ·  12-11
Geron Corp: Restructuring Plan Is Expected to Be Substantially Complete in Q1 of 2026
Press Release: Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Dow Jones  ·  12-11
Press Release: Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Geron Corporation Reports on IL-8 and TNF-Alpha Correlation with Survival in Myelofibrosis Patients Treated with Imetelstat
Reuters  ·  12-08
Geron Corporation Reports on IL-8 and TNF-Alpha Correlation with Survival in Myelofibrosis Patients Treated with Imetelstat
Geron Corporation Releases Phase 1b Trial Results on Imetelstat Plus Ruxolitinib for Myelofibrosis
Reuters  ·  12-08
Geron Corporation Releases Phase 1b Trial Results on Imetelstat Plus Ruxolitinib for Myelofibrosis
Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes
Reuters  ·  12-08
Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes
Geron Unveils New Data Showing RYTELO Improves Outcomes in Lower-Risk MDS
Reuters  ·  12-08
Geron Unveils New Data Showing RYTELO Improves Outcomes in Lower-Risk MDS
Geron Q3 EPS USD -0.03
Reuters  ·  11-20
Geron Q3 EPS USD -0.03
Wedbush Cuts Price Target on Geron to $5 From $6, Keeps Outperform Rating
MT Newswires Live  ·  11-06
Wedbush Cuts Price Target on Geron to $5 From $6, Keeps Outperform Rating
Stock Track | Geron Soars 9.17% Pre-Market Following Q3 Earnings and Positive Analyst Outlook
Stock Track  ·  11-06
Stock Track | Geron Soars 9.17% Pre-Market Following Q3 Earnings and Positive Analyst Outlook

Introduction

Company Name.
Geron
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Issue price:
--